Antisense Oligonucleotide Therapeutics Market Size, Share and Growth Factors Study

Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease and Others), Trends, Industry Competition Analysis, Revenue and Forecast To 2024-2030."

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1245

Insight Analytics estimated the global market for antisense oligonucleotide therapeutics to be worth US$21.91 billion in 2024. With a prediction period of 2024-2031 and a compound annual growth rate of 12.9%, it is anticipated to reach US$64.64 billion by 2030. Antisense oligonucleotides are short, single-stranded DNA or RNA molecules. Although antisense oligonucleotides do not change the activity of already synthesized proteins, they act at the level of messenger RNA in the cell before the formation of proteins. Antisense oligonucleotides treat inflammatory conditions, diabetes, asthma, hair loss, and neurological disorders.

Antisense oligonucleotides are also used in genomics. Among the antisense nucleotides are mipomersen, used to treat excessive cholesterol, and fomivirsen, used to treat CMV retinitis.

Because antisense oligonucleotides work on messenger RNA before protein synthesis, they inhibit the expression of genes that cause disease. This makes them crucial to modern medicine. The market is impacted by neurological disorders, ageing populations, growing funding for research and development, and growing consumer acceptance of antisense medications. The antisense oligonucleotide industry will benefit from the multiple regulatory licenses issued by the Food and Drug Administration (FDA) to use innovative antisense oligonucleotide medications.

Additionally, mergers and acquisitions to broaden businesses' product offerings over the next several years would propel the global market for antisense oligonucleotides. In the coming years, two issues are expected to limit the trend of the antisense oligonucleotide therapeutics market: the accessibility of synthetic chemicals and the high cost of these therapies.

Another obstacle to the progress of the worldwide antisense oligonucleotide market is the development of new regulatory regulations. Moreover, it is projected that during the forecast period, notable players' investments will provide lucrative opportunities for revenue growth for firms engaged in the antisense oligonucleotide therapeutics market. Over time, Europe is expected to have a role in the Antisense Oligonucleotide Therapeutics market. This is a consequence of the field's growing acceptance of novel antisense oligonucleotide medications. Prominent European corporations focus on strategic acquisitions and mergers while enhancing their antisense oligonucleotide product lines.

Furthermore, throughout the forecast period, it is anticipated that the Antisense Oligonucleotide Therapeutics market in North America will expand considerably. Several biotechnology companies have made significant financial investments to develop RNAi treatments.

Massive pharmaceutical companies have partnered with or licensed several smaller companies to capitalize on the projected revenue growth in this market throughout the forecast period. Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Sarna Therapeutics GmbH, Gradualist, ICO Therapeutics, Aptos Biosciences, Enzo Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, Marina Biotech, mirage Therapeutics, Inc., Synodic, Inc., Oncogene Pharmaceuticals Inc., Pharm axis Ltd, Regulus Therapeutics Inc., Reran Pharmaceuticals, Inc., and RI Pharmaceuticals are some of the prominent market players involved in the Antisense Oligonucleotide Therapeutics market.

Recent collaborations and agreements in the market:

• In January 2021, MilliporeSigma (US) acquired AmpTec, a well-known German business specializing in contract development and manufacturing mRNA (CDMO).

• In August 2019, Integrated DNA Technology released tools- oligo pools, a set of 350-nucleotide-long, high-quality DNA oligonucleotides (US).
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1245
Market Segments

Global Antisense Oligonucleotide Therapeutics Market, by Therapy, 2022-2030 (Value US$ Mn)

• Monotherapy
• Combination

Global Antisense Oligonucleotide Therapeutics Market, by Molecule Target Indication, 2022-2030 (Value US$ Mn)

• DNA Molecule
• RNA Molecule

Global Antisense Oligonucleotide Therapeutics Market, by Target Indication, 2022-2030 (Value US$ Mn)

• Duchenne Muscular Atrophy
• Spinal Muscular Atrophy
• Familial Chylomicronemia Syndrome
• Amyotrophic Lateral Sclerosis
• Familial Partial Lipodystrophy
• Hereditary Transthyretin-Mediated (hatter) Amyloidosis
• Huntington's Disease
• Others

Global Antisense Oligonucleotide Therapeutics Market, by Region, 2022-2030 (Value US$ Mn)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• U.S.
• Canada

Europe Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Antisense Oligonucleotide Therapeutics Market, by Country, 2022-2030 (Value US$ Mn)

• GCC Countries
• South Africa
o Rest of Middle East & Africa
Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Antisense Oligonucleotide Therapeutics market
 To receive an industry overview and future trends in the Antisense Oligonucleotide Therapeutics market
 To analyze the Antisense Oligonucleotide Therapeutics market drivers and challenges
 To get information on the Antisense Oligonucleotide Therapeutics market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Antisense Oligonucleotide Therapeutics market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1245

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.